Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 13,700 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 13,700 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total transaction of $134,534.00. Following the completion of the sale, the executive vice president directly owned 112,982 shares in the company, valued at approximately $1,109,483.24. The trade was a 10.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, February 24th, Verneuil Vanina De sold 3,117 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.53, for a total transaction of $29,705.01.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $33,115.25.

Vir Biotechnology Price Performance

NASDAQ VIR opened at $9.29 on Friday. The company’s 50 day simple moving average is $6.95 and its two-hundred day simple moving average is $6.04. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94. The stock has a market capitalization of $1.30 billion, a PE ratio of -2.96 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter in the prior year, the firm posted ($0.76) earnings per share. The business’s quarterly revenue was up 417.8% on a year-over-year basis. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors have recently made changes to their positions in VIR. ARCH Venture Management LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter valued at $65,100,000. GSK plc bought a new position in shares of Vir Biotechnology during the fourth quarter valued at about $51,562,000. Balyasny Asset Management L.P. bought a new position in shares of Vir Biotechnology during the fourth quarter valued at about $8,252,000. State Street Corp increased its holdings in shares of Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after buying an additional 988,262 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Vir Biotechnology by 129.2% in the 3rd quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after acquiring an additional 787,212 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration with Vir on the prostate‑cancer asset (VIR‑5500) includes up‑front/near‑term payments and up to about $1.7 billion in contingent milestones — a material de‑risking and commercialization path for a late‑stage asset. Read More.
• Positive Sentiment: Quarterly results beat expectations: Q4 revenue (~$64M) and EPS topped consensus, signaling improving commercial traction and supporting higher analyst enthusiasm. Read More.
• Positive Sentiment: Analyst upgrades and target increases followed the news (Needham raised its target to $18), boosting upside sentiment despite current volatility. Read More.
• Neutral Sentiment: Management will present at investor conferences in early March (TD Cowen, Leerink), which can provide clarity but are not a fundamental catalyst by themselves. Read More.
• Neutral Sentiment: Comparative coverage and peer analyses are increasing visibility and trading volume (e.g., head‑to‑head pieces with peers), but they don’t change Vir’s underlying cash flow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross proceeds). The discounted placement strengthens the balance sheet but is dilutive and increases near‑term share supply, pressuring the stock. Read More.
• Negative Sentiment: Coverage noted the discounted offering as the proximate cause of the post‑rally pullback/tumble, amplifying short‑term selling. Read More.
• Negative Sentiment: Significant insider selling was disclosed (multiple officers and a director reported sales last week), which—combined with the offering—added visible supply and negative sentiment. Read More.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on VIR shares. Needham & Company LLC lifted their price target on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. Barclays increased their price target on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price for the company in a research report on Tuesday. Finally, Leerink Partners restated an “outperform” rating and set a $20.00 price target on shares of Vir Biotechnology in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.89.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.